Sun Pharma Advanced Research Company Ltd. announced that an abstract on updated safety and efficacy outcomes of vodobatinib in refractory chronic myeloid leukemia (CML) subjects has been selected for oral presentation at the 63rd American Society of Hematology (ASH) Annual Meeting. The Phase 1 study outcomes will be presented by Prof. Jorge Cortes, the Principal Investigator for the study, on 11 Dec 2021. Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of vodobatinib for the treatment of heavily pre-treated CML. Vodobatinib is a novel, third generation, selective BCR-Abl1 tyrosine kinase inhibitor (TKI) developed by SPARC for the treatment of patients with CML who are resistant or intolerant to 3 TKIs or ineligible for TKIs. Majority of the CML patients enrolled in the Phase 1 study had failed 3 TKIs. Similar anti-leukemic activity (major cytogenetic response 60%) was observed in CML-CP patients with or without prior ponatinib treatment. The current abstract provides longer term safety and efficacy updates to vodobatinib therapy. Vodobatinib has been granted Orphan Drug Designation for treatment of CML patients by USFDA and EMA. A Phase 2 study has been initiated and is recruiting globally. An update of safety and efficacy results from Phase 1 dose-escalation and expansion study of Vodobatinib, a novel oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) failing prior TKI therapies.